Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer

Human Gene Therapy

Volumn 23, Issue 12, 2012, Pages 1258-1268

  Bunuales, Maria ^a   Garcia Aragoncillo, Eva ^a   Casado, Raquel ^a   Quetglas, José Ignacio ^a   Hervas Stubbs, Sandra ^a   Bortolanza, Sergia ^a,d   Benavides Vallve, Carolina ^b   Ortiz De Solorzano, Carlos ^b   Prieto, Jesus ^a,c   Hernandez Alcoceba, Ruben ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; INTERLEUKIN 12; LUCIFERASE; NEUTRALIZING ANTIBODY; ONCOLYTIC ADENOVIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER MODEL; CELL BASED GENE THERAPY; CELL LINE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER METASTASIS; MONOCYTE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS TUMOR; PROTECTION; SYRIAN HAMSTER; TRANSGENE; TUMOR XENOGRAFT; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CRICETINAE; GENE EXPRESSION; HUMANS; INTERLEUKIN-12; MESOCRICETUS; MICE; MICE, NUDE; MONOCYTES; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIROTHERAPY; PANCREATIC NEOPLASMS; TRANSGENES; TRANSPLANTS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; CRICETINAE; MESOCRICETUS AURATUS; MURINAE; MUS;

EID: 84871241697     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.043     Document Type: Article

References (29)

1. Ahmed, A.U., Rolle, C.E., Tyler, M.A., et al. (2010). Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol. Ther. 18, 1846-1856.
2. Ahmed, A.U., Tyler, M.A., Thaci, B., et al. (2011). A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol. Pharm. 8, 1559-1572.
3. Alemany, R., and Cascallo, M. (2009). Oncolytic viruses from the perspective of the immune system. Future Microbiol. 4, 527-536.
4. Appaiahgari, M.B., Pandey, R.M., and Vrati, S. (2007). Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines. Clin. Vaccine Immunol. 14, 1053-1055.
5. Bortolanza, S., Alzuguren, P., Bunuales, M., et al. (2007). Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters. Hum Gene Ther. 18, 681-90.
6. Bortolanza, S., Bunuales, M., Alzuguren, P., et al. (2009a). Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters. Cancer Gene Ther. 16, 703-712.
7. Bortolanza, S., Bunuales, M., Otano, I., et al. (2009b). Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther. 17, 614-622.
8. Breitbach, C.J., Burke, J., Jonker, D., et al. (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 477, 99-102.
9. Dwyer, R.M., and Kerin, M.J. (2010). Mesenchymal stem cells and cancer: tumor-specific delivery vehicles or therapeutic targets? Hum. Gene Ther. 21, 1506-1512.
10. Eager, R.M., and Nemunaitis, J. (2011). Clinical development directions in oncolytic viral therapy. Cancer Gene Ther. 18, 305-317.
11. Fontanellas, A., Hervas-Stubbs, S., Mauleon, I., et al. (2010). Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates. Mol. Ther. 18, 754-765.
12. Fueyo, J., Gomez-Manzano, C., Alemany, R., et al. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 19, 2-12.
13. Hawkins, L.K., Johnson, L., Bauzon, M., et al. (2001). Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region. Gene Ther. 8, 1123-1131.
14. Heise, C., Hermiston, T., Johnson, L., et al. (2000). An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med. 6, 1134-1139.
15. Josiah, D. T., Zhu, D., Dreher, F., et al. (2010). Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Mol Ther. 18, 377-385.
16. Lei, N., Shen, F.B., Chang, J.H., et al. (2009). An oncolytic adenovirus expressing granulocyte macrophage colonystimulating factor shows improved specificity and efficacy for treating human solid tumors. Cancer Gene Ther. 16, 33-43.
17. Liu, C., Russell, S.J., and Peng, K.W. (2010). Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther. 18, 1155-1164.
18. Murdoch, C., and Lewis, C.E. (2005). Macrophage migration and gene expression in response to tumor hypoxia. Int. J. Cancer. 117, 701-708.
19. Muthana, M., Giannoudis, A., Scott, S.D., et al. (2011). Use of macrophages to target therapeutic adenovirus to human prostate tumors. Cancer Res. 71, 1805-1815.
20. Narvaiza, I., Aparicio, O., Vera, M., et al. (2006). Effect of adenovirus-mediated RNA interference on endogenous micro-RNAs in a mouse model of multidrug resistance protein 2 gene silencing. J. Virol. 80, 12236-12247.
21. Penuelas, I., Mazzolini, G., Boan, J.F., et al. (2005). Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology. 128, 1787-1795.
22. Raykov, Z., and Rommelaere, J. (2008). Potential of tumour cells for delivering oncolytic viruses. Gene Ther. 15, 704-710.
23. Senzer, N. N., Kaufman, H. L., Amatruda, T., et al. (2009). Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27, 5763-5771.
24. Sprangers, M.C., Lakhai, W., Koudstaal, W., et al. (2003). Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 41, 5046-5052.
25. Sun, C., Zhang, Y., Feng, L., et al. (2011). Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Vaccine. 29, 3837-3841.
26. Thomas, M.A., Spencer, J.F., La Regina, M.C., et al. (2006). Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res. 66, 1270-1276.
27. Thorne, S.H., Liang, W., Sampath, P., et al. (2010). Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy. Mol Ther. 18, 1698-1705.
28. Thorner, A.R., Vogels, R., Kaspers, J., et al. (2006). Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J. Clin. Microbiol. 44, 3781-3783.
29. Zabala, M., Alzuguren, P., Benavides, C., et al. (2009). Evaluation of bioluminescent imaging for noninvasive monitoring of colorectal cancer progression in the liver and its response to immunogene therapy. Mol. Cancer. 8, 2.